Resmetirom

Type: API

Usage: Fatty liver, non-alcoholic hepatitis

Technical description
Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD. Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation.

IUPAC name: 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile.

Molecular formula: C₁₇H₁₂Cl₂N₆O₄

Molecular Weight: 2 g/mol

Class: A selective agonist of the thyroid hormone receptor β (THR-β).

Synonyms: MGL-3196 and VIA-3196.